{"prompt": "['2.', 'Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2018. CA Cancer J Clin,', '2018. 68(1): p. 7-30.', '3.', 'Storkel, S. and E. van den Berg, Morphological classification of renal cancer. World', 'J Urol, 1995. 13(3): p. 153-8.', '4.', 'Gnarra, J.R., et al., Mutations of the VHL tumour suppressor gene in renal', 'carcinoma. Nat Genet, 1994. 7(1): p. 85-90.', '5.', 'Sufan, R.I., M.A. Jewett, and M. Ohh, The role of von Hippel-Lindau tumor', 'suppressor protein and hypoxia in renal clear cell carcinoma. Am J Physiol Renal', 'Physiol, 2004. 287(1): p. F1-6.', '6.', 'Motzer, R.J., et al., Sunitinib versus interferon alfa in metastatic renal-cell', 'carcinoma. N Engl J Med, 2007. 356(2): p. 115-24.', '7.', 'Sternberg, C.N., et al., Pazopanib in locally advanced or metastatic renal cell', 'carcinoma: results of a randomized phase III trial. J Clin Oncol, 2010. 28(6): p.', '1061-8.', '8.', 'Rini, B.I., et al., Bevacizumab plus interferon alfa compared with interferon alfa', 'monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin', 'Oncol, 2008. 26(33) p. 5422-8.', '9.', 'Choueiri, T.K., et al., Cabozantinib Versus Sunitinib As Initial Targeted Therapy for', 'Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The', 'Alliance A031203 CABOSUN Trial. J Clin Oncol, 2017. 35(6): p. 591-597.', '10.', 'Motzer, R.J., et al., Lenvatinib, everolimus, and the combination in patients with', 'metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.', 'Lancet Oncol, 2015. 16(15) p. 1473-82.', '11.', 'Kudo, M., et al., Lenvatinib versus sorafenib in first-line treatment of patients with', 'unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.', 'Lancet, 2018. 391(10126): p. 1163-1173.', '12.', 'Schlumberger, M., et al., Lenvatinib versus placebo in radioiodine-refractory thyroid', 'cancer. N Engl J Med, 2015. 372(7): p. 621-30.', '13.', 'ps://investors.merck.com/news/press-release-details/2019/FDA-Approves-', 'KEYTRUDA-pembrolizumab-plus-LENVIMA-lenvatinib-Combination-Treatn', 'Patients-with-Certain-Types-of-Endometrial-Carcinoma/default.aspx.', '14.', 'Gleave, M.E., et al., Interferon gamma-le compared with placebo in metastatic', 'renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med, 1998.', '338(18): p. 1265-71.', '15.', 'Vogelzang, N.J., E.R. Priest, and L. Borden, Spontaneous regression of histologically', 'proved pulmonary metastases from renal cell carcinoma: a case with 5-year', 'followup. J Urol, 1992. 148(4): p. 1247-8.', '16.', 'Fyfe, G., et al., Results of treatment of 255 patients with metastatic renal cell', 'carcinoma who received high-dose recombinant interleukin-2 therapy. Journal of', 'Clinical Oncology, 1995. 13(3): p. 688-696.', '17.', 'Wierecky, J., et al., Immunologic and clinical responses after vaccinations with', 'peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res, 2006.', '66(11): p. 5910-8.', '18.', 'Labriola, M.K., et al., Immunotherapy Is Changing First-Line Treatment of', 'Metastatic Renal-Cell Carcinoma. Clin Genitourin Cancer, 2019. 17(3): p. e513-', 'e521.', '71']['19.', 'Yarchoan, M., et al., PD-L1 expression and tumor mutational burden are independent', 'biomarkers in most cancers. JCI Insight, 2019. 4(6).', '20.', 'Motzer, R.J., et al., Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-', 'Cell Carcinoma. N Engl J Med, 2018. 378(14): p. 1277-1290.', '21.', 'Unnikrishnan, R.R., P.; Yang, Y.; Diaz-Montero, C. M.; and Finke, J., Pazopanib,', 'sunitinib, and axitinib reduce expansion of in vitro induced suppressive macrophages', 'The Journal of Urology, 2015. 193(4S): p. 3712.', '22.', 'Bracarda, S., et al., Angiogenic and immunological pathways in metastatic renal cell', 'carcinoma: A counteracting paradigm or two faces of the same medal? The GIANUS', 'Review. Crit Rev Oncol Hematol, 2019. 139: p. 149-157.', '23.', 'Kimura, T., et al., Immunomodulatory activity of lenvatinib contributes to antitumor', 'activity in the Hepal-6 hepatocellular carcinoma model. Cancer Sci, 2018. 109(12):', 'p. 3993-4002.', '24.', 'Rini, B.I., et al., Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-', 'Cell Carcinoma. N Engl J Med, 2019. 380(12) p. 1116-1127.', '25.', 'Motzer, R.J., et al., Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell', 'Carcinoma. N Engl J Med, 2019. 380(12) p. 1103-1115.', '26.', 'Lee, C.-H., et al., Lenvatinib + pembrolizumab in patients with renal cell carcinoma:', 'Updated results. Journal of Clinical Oncology, 2018. 36(15_suppl): p. 4560-4560.', '27.', 'Grunwald, V., et al., Lenvatinib plus everolimus or pembrolizumab versus sunitinib in', 'advanced renal cell carcinoma: study design and rationale. Future Oncol, 2019.', '15(9): p. 929-941.', '28.', 'Ravaud, A., et al., Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after', 'Nephrectomy. N Engl J Med, 2016.375(23) p. 2246-2254.', '29.', 'NCCN, Kidney Cancer (Version 2.2020). National Comprehensive Cancer Network,', '2019.', '30.', 'Lane, B.R., et al., Presurgical sunitinib reduces tumor size and may facilitate partial', 'nephrectomy in patients with renal cell carcinoma. Urol Oncol, 2015. 33(3): p.', '112.e15-21.', '31.', 'Rini, B.I., et al., A Phase II Study of Pazopanib in Patients with Localized Renal Cell', 'Carcinoma to Optimize Preservation of Renal Parenchyma. J Urol, 2015. 194(2): p.', '297-303.', '32.', 'Karam, J.A., et al., Phase 2 trial of neoadjuvant axitinib in patients with locally', 'advanced nonmetastatic clear cell renal cell carcinoma. Eur Urol, 2014. 66(5): p.', '874-80.', '33.', 'Harshman, L.C., et al., PROSPER: A phase III randomized study comparing', 'perioperative nivolumab (nivo) versus observation in patients with localized renal', 'cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143). Journal of', 'Clinical Oncology, 2019. 37(7_suppl) p. TPS684-TPS684.', '34.', 'Necchi, A., et al., Pembrolizumab as Neoadjuvant Therapy Before Radical', 'Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-', '01): An Open-Label, Single-Arm, Phase II Study. J Clin Oncol, 2018: p. Jco1801148.', '35.', 'Sarafidis, P.A., N. Khosla, and G.L. Bakris, Antihypertensive therapy in the presence', 'of proteinuria. Am J Kidney Dis, 2007. 49(1): p. 12-26.', '36.', 'http://cancer.unc.edu/biostatistics/program/ivanova/SimonsTwoStageDesign.aspx', '72']\n\n###\n\n", "completion": "END"}